抗血管生成药物在铂耐药卵巢癌中的应用进展

doi:10.11904/j.issn.1002-3070.2020.01.011

实用肿瘤学杂志 ›› 2020, Vol. 34 ›› Issue (1): 60-63.doi: 10.11904/j.issn.1002-3070.2020.01.011

抗血管生成药物在铂耐药卵巢癌中的应用进展

梁永琴¹, 赵宏伟²

1.山西医科大学(太原 030000);
2.山西省肿瘤医院

收稿日期:2019-09-10 修回日期:2019-11-25 出版日期:2020-02-28 发布日期:2020-02-20
通讯作者: 赵宏伟,E-mail:inmind20060829@126.com
作者简介:梁永琴,女,(1994-),硕士,住院医师,从事妇科肿瘤的研究。
基金资助:
山西省留学回国人员科技活动择优资助项目;CSCO-恒瑞肿瘤研究基金(编号:Y-HR2018-330);山西省重点研发计划项目(编号:201903D321174)

Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer

LIANG Yongqin¹, ZHAO Hongwei²

1.Shanxi Medical University,Taiyuan 030000,China;
2.Shanxi Provincial Cancer Hospital

Received:2019-09-10 Revised:2019-11-25 Online:2020-02-28 Published:2020-02-20

摘要/Abstract

摘要： 化疗药物在铂耐药卵巢癌治疗中应用非常局限,近年来,多项试验表明抗血管生成药物有改善铂耐药卵巢癌患者预后的作用。本文根据作用机制的不同,把抗血管生成药物分为血管内皮生长因子抑制剂、血管内皮生长因子受体抑制剂、酪氨酸激酶抑制剂和整合素抑制剂,分别阐述其在铂耐药卵巢癌治疗中的研究进展。

关键词: 卵巢癌, 抗血管生成药物, 耐药

Abstract: Chemotherapy drugs are very limited in the treatment of platinum-resistant ovarian cancer.In recent years,several trials have shown that antiangiogenic drugs can effectively improve the prognosis of patients with drug-resistant ovarian cancer.According to different mechanisms of action,antiangiogenic drugs are divided into vascular endothelial growth factor inhibitors,vascular endothelial growth factor receptor inhibitors,tyrosine kinase inhibitors and integrin inhibitors,and described the research progress of antiang iogenic drugs in the treatment of platinum-resistant ovarian cancer.

Key words: Ovarian cancer, Antiangiogenic drugs, Drug resistance

中图分类号:

R737.31

梁永琴, 赵宏伟. 抗血管生成药物在铂耐药卵巢癌中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 60-63.

LIANG Yongqin, ZHAO Hongwei. Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer[J]. Journal of Practical Oncology, 2020, 34(1): 60-63.

参考文献

1 赵玲军.卵巢癌靶向治疗新进展[J].现代实用医学,2019,31(7):854-857.
2 罗丹,孔民.复发性卵巢癌治疗的研究进展[J].癌症进展,2019,17(17):2003-2006.
3 Takasaki K,Miyamoto M,Takano M,et al.Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer:a retrospective analysis[J].Cancer Chemother Pharmacol,2018,81(5):809-814.
4 张志方,席晓薇,祖剑飞,等.复发性上皮性卵巢癌的药物治疗及进展[J].实用药物与临床,2019,22(5):452-455.
5 Gadducci A,Lanfredini N,Sergiampietri C.Antiangiogenic agents in gynecological cancer:State of art and perspectives of clinical research[J].Crit Rev Oncol Hematol,2015,96(1):113-128.
6 Randall LM,Monk BJ.Bevacizumab toxicities and their management in ovarian cancer[J].Gynecol Oncol,2010,117(3):497-504.
7 Crothey A,Ellis LM.Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies[J].Cancer J,2008,14(3):170-177.
8 Pujade LE,Hilpert F,Weber B,et al.Bevacizumab combined with chemotherapy for platinumresistant recurrent ovarian cancer:the AURELIA open-label randomized phase III trial[J].Clin Oncol,2014,32(13):1302-1308.
9 Broglio KR,Berry DA.Detecting an overall survival benefit that is derived from progression-free survival[J].J Natl Cancer Inst,2009,101(23):1642-1649.
10 Kenro C,Sachiho N,Tomoyuki K,et al.Bevacizumab improves overall survival in platinum refractory ovarian cancer patients:A retrospective study[J].Taiwan J Obstet Gynecol,2018,57(6):819-824.
11 Barber EL,Zsiros E,Lurain JR,et al.The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer[J].Gynecol Oncol,2013,24(3):258-264.
12 卢淮武,霍楚莹,林仲秋.《2019NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J].中国实用妇科与产科杂志,2019,35(5):536-546.
13 Cohen S,Schwartz M,Dottino P,et al.Use of a multi-drug regimen gemcitabine,5-fluorouracil,irinotecan,cisplatin,bevacizumab,docetaxel,and cyclophosphamide(GFIP/BDC)for heavily pretreated relapsed epithelial ovarian,fallopian tube and primary peritoneal cancer[J].Ovarian Res,2019,12(1):36.
14 张亚会,孙文广.生育三烯酚抗肿瘤作用研究进展[J].癌症进展,2017,15(6):614-617.
15 Caroline BT,Rikke FA,Karina DS,et al.Delta tocotrienol in recurrent ovarian cancer.A phase II trial[J].Pharmacol Res,2019,141:392-396.
16 李瑶,朱壮彦.生育三烯酚在宫颈癌中的研究进展[J].临床医药文献电子杂志,2017,4(14):2754-2755.
17 Wang HP,Sun SL,Zhang Y,et al.Improved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticles[J].Drug Deliv,2019,26(1):89-97.
18 Radoslav C,Felix H,Sven M,et al.Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer(TRIAS):a multicentre,randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet,2018,19(9):1247-1258.
19 Miao M,Deng G,Luo S,et al.A phase II study of apatinib in patients with recurrent epithelial ovarian cancer[J].Gynecol Oncol,2018,148(2):286-290.
20 Chun YL,Yin W,Ying X,et al.Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer(AEROC):a phase 2,single-arm,prospective study[J].Lancet Oncol,2018,19(9):1239-1246.
21 Liu JF,Tolaney SM,Birrer M,et al.A Phase 1 trial of the poly(ADP-ribose)polymerase inhibitor olaparib(AZD2281)in combination with the anti-angiogenic cediranib(AZD2171)in recurrent epithelial ovarian or triple-negative breast cancer[J].Eur J Cancer,2013,49(14):2972-2978.
22 Monk BJ,Poveda A,Vergote I,et al.Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer(TRINOVA-1):a randomised,multicentre,double-blind,placebo-controlled phase 3 trial[J].Lancet Oncol,2014,15(8):799-808.
23 Marth C,Vergote I,Scambia G,et al.ENGOT-ov-6/TRINOVA-2:Randomised,double-blind,phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer[J].Eur J Cancer,2017,70(complete):111-121.
24 Scalici JM,Harrer C,Allen A,et al.Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin[J].Gynecol Oncol,2014,132(2):455-461.

[1]	黄梨, 龙佑梅, 付义霞, 夏良斌. 紫檀芪对卵巢癌SKOV3细胞凋亡和糖酵解的影响及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 502-507.
[2]	邓明新, 张颖. 环状RNA与卵巢癌研究新进展[J]. 实用肿瘤学杂志, 2019, 33(6): 549-552.
[3]	张慧婷, 娄阁. 卵巢癌肿瘤微环境的三维细胞培养模型研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 557-560.
[4]	宋玲, 付琼. 紫云英苷通过上调PHD2抑制缺氧诱导的卵巢癌细胞增殖和侵袭[J]. 实用肿瘤学杂志, 2019, 33(5): 407-414.
[5]	黄显博, 史庭 , 叶琇锦. 靶向PI3K/AKT/mTOR信号通路治疗急性T淋巴细胞白血病的研究进展[J]. 实用肿瘤学杂志, 2019, 33(5): 451-455.
[6]	李磊 , 张清媛. 乳腺癌抗肿瘤血管治疗的临床进展[J]. 实用肿瘤学杂志, 2019, 33(5): 461-465.
[7]	张蓓蕾, 李怡, 吴涛, 姜锋, 赵宏喜, 李艳红. 血根碱通过诱导细胞凋亡抑制卵巢癌肿瘤生长的机制研究[J]. 实用肿瘤学杂志, 2019, 33(4): 305-309.
[8]	吕博文, 钱钧, 王杰, 钱景荣, 卢莹莹, 苏丽菊, 杨桐树, 李文辉. miR-455-5p在上皮性卵巢癌中表达研究及其靶基因功能分析[J]. 实用肿瘤学杂志, 2019, 33(2): 115-121.
[9]	宋玲, 付琼. 紫云英苷通过抑制HIF-1α诱导的糖酵解途径发挥抗卵巢肿细胞作用的研究[J]. 实用肿瘤学杂志, 2018, 32(6): 503-509.
[10]	姜亮亮综述, 王晶审校. 上皮性卵巢癌远处转移的诊治进展[J]. 实用肿瘤学杂志, 2018, 32(5): 480-482.
[11]	梁冠盈, 迟秋君, 李晓梅. 伏立诺他对卵巢癌SKOV3细胞增殖和凋亡的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(4): 298-302.
[12]	李文辉, 吕博文, 钱钧, 苏丽菊, 杨桐树, 钱景荣, 王杰. MicroRNA-150对上皮性卵巢癌细胞增殖、凋亡和侵袭转移能力的影响[J]. 实用肿瘤学杂志, 2018, 32(3): 208-213.
[13]	毕琦玲, 周立红, 韩毅敏. HOX基因与妇科肿瘤的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 140-143.
[14]	陈丹, 李加桩, 隋红. 阿帕替尼多重癌1例附文献回顾[J]. 实用肿瘤学杂志, 2017, 31(5): 441-443.
[15]	孙丽娜, 赵晓迪综述, 卢瑗瑗, 王新审校. LncRNA与胃肠道肿瘤化疗耐药的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 448-453.

抗血管生成药物在铂耐药卵巢癌中的应用进展

Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价